Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors in juvenile idiopathic arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Prognostic factors in juvenile arthritis are related to many variables that must be evaluated according to the different subtypes. The International League of Associations of Rheumatologists (ILAR) recently proposed six different categories referred to as the Durban criteria, under the eponym of juvenile idiopathic arthritis (JIA). The aim of this classification was to define homogeneous groups according to their clinical and biologic features. The prognostic factors were classified into the different categories of JIA. A poor outcome in the systemic form correlated with markers of disease activity, such as fever and polyarticular involvement, within the first 6 months. The risk of joint destruction in oligoarthritis correlated with the severity of arthritis within the first 2 years. Polyarthritis with positive rheumatoid factor is associated with marked disability in adulthood. In a group of psoriatic patients, the risk of developing sacroiliitis is higher in male and HLA-B27-positive patients. Patients with enthesitis-related arthritis with lower limb, knee, and tarsal involvement also are at greater risk of developing sacroiliitis. Chronic uveitis is a complication of JIA observed mainly in patients with oligoarthritis associated with positive antinuclear antibodies in serum. Secondary amyloidosis is observed mainly in children with systemic JIA. The long-term outcome must be discussed according to the various therapies. Corticosteroids contribute to growth retardation and osteoporosis, for which the use of human recombinant growth hormone and biphosphonates may be an option. Newer encouraging therapies such as anticytokines have been proposed for children with active disease. Autologous stem cell transplantation is being evaluated in some centers with promising results; however, it has a high rate of mortality. Further discussion regarding which patients should undergo autologous stem cell transplantion is needed, as is further discussion regarding the technical adaptations necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Ansell BM: Prognosis in juvenile arthritis. Adv Exp Med Biol 1999, 455:27–33.

    PubMed  CAS  Google Scholar 

  2. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998, 25:1991–1994. The classification of childhood arthritis previously proposed at a meeting in Santiago in 1994 was reassessed at the second meeting of the Pediatric Standing Committee of ILAR held in Durban in 1997. This classification was discussed according to the opinion of different experienced pediatric rheumatologists from around the world and according to criticisms addressed to the Santiago proposals. A list of descriptors, i.e. characteristics that may be of importance for further definition of the disease were listed for each category.

    PubMed  CAS  Google Scholar 

  3. Hofer M, Mouy R, Prieur AM: Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 2001, 28:1083–1090.

    PubMed  CAS  Google Scholar 

  4. Lomater C, Gerloni V, Gattarina M, et al.: Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000, 27:491–496.

    PubMed  CAS  Google Scholar 

  5. Cabane J, Michon A, Ziza JM, et al.: Comparison of long term evolution of adult and juvenile onset Still’s disease, both follow up for more than 10 years. Ann Rheum Dis 1990, 49:283–285.

    Article  PubMed  CAS  Google Scholar 

  6. Lin SJ, Chao HC, Yan DC: Different articular outcomes of Still’s disease in Chinese children and adults. Clin Rheumatol 2000, 19:127–130.

    Article  PubMed  CAS  Google Scholar 

  7. Spiegel LR, Schneider R, Lang BA, et al.: Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000, 43:2402–2409.

    Article  PubMed  CAS  Google Scholar 

  8. Modesto C, Woo P, Garcia-Consuegra J, et al.: Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for bad prognosis. Clin Exp Rheumatol 2001, 19:211–217. From 124 patients with systemic onset observed in three different European centers, 91 were eligible for a retrospective evaluation of predictors for poor outcome by collecting clinical and laboratory features at onset, at 3 months, and at 6 months. The proposal of an easy clinical score from 0 to 6 at onset, if confirmed, should improve further strategies for these patients’ management.

    PubMed  CAS  Google Scholar 

  9. Sharma S, Sherry DD: Joint distribution at presentation in children with pauciarticular arthritis. J Pediatr 1999, 134:642–643.

    Article  PubMed  CAS  Google Scholar 

  10. Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology 2000, 39:198–204.

    Article  PubMed  CAS  Google Scholar 

  11. Guillaume S, Prieur AM, Coste J, Job-Deslandre C: Long term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:1858–1865. This study gathered together 207 patients observed in two pediatric rheumatology units in Paris. Clinical and laboratory data observed at onset were recorded. Other features at follow-up were the number of arthritis in a cumulative total, the occurrence of joint destruction on radiographs, and the presence of uveitis at systematic slit lamp examination. Multivariate analysis using the Cox model identified three independent factors of disease severity: two to four affected joints, upper limb involvement, and high ESR.

    Article  PubMed  CAS  Google Scholar 

  12. Musiej-Nowakoska E, Ploski R: Pregnancy and early onset pauciarticular chronic arthritis. Ann Rheum Dis 1999, 58:475–480.

    Article  Google Scholar 

  13. Ravelli A, Viola S, Migliavacca D, et al.: The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999, 135:316–320.

    Article  PubMed  CAS  Google Scholar 

  14. Woo P, Southwood TR, Prieur AM, et al.: Randomized, placebo-controlled, crossover trial low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000, 43:1846–1857.

    Article  Google Scholar 

  15. David J, Cooper C, Hickey L, et al.: The functional and psychological outcomes of juvenile chronic arthritis in young adulthood. Br J Rheumatol 1994, 33:876–881.

    Article  PubMed  CAS  Google Scholar 

  16. Kennedy LG, Will R, Calin A: Sex ratio in the spondylarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993, 20:1900–1904.

    PubMed  CAS  Google Scholar 

  17. Shore A, Ansell BM: Juvenile psoriatic arthritis: an analysis in 60 cases. J Pediatr 1982, 100:529–535.

    Article  PubMed  CAS  Google Scholar 

  18. Hamilton ML, Gladman DD, Shore A, et al.: Juvenile psoriatic arthritis and HLA antigens. Ann Rheum Dis 1990, 49:694–697.

    Article  PubMed  CAS  Google Scholar 

  19. Roberton DM, Cabral DA, Malleson PN, Petty RE: Juvenile psoriatic arthritis: follow-up and evaluation of diagnostic criteria. J Rheumatol 1996, 23:166–170. A series of 63 patients with definite psoriatic arthritis (PsA) (50) and probable PsA (13), including 34 patients previously reported by Southwood et al., was analyzed after an average follow-up of 6.1 years. Probable PsA at onset in 11 of 24 patients evolved to definite PsA after a median of 2.1 years. The arthritis pattern of the patients remaining classified as probable PsA did not differ significantly from the group with definite PsA.

    PubMed  CAS  Google Scholar 

  20. Rosenberg AM, Petty RE: A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982, 25:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  21. Prieur AM, Listrat V, Dougados M, Amor B: Evaluation of four sets of criteria for spondylarthropathy in children: a multicentre European cross-sectional study. Arthritis Rheum 1992, 35:S190.

    Article  Google Scholar 

  22. Edmonds J, Morris RI, Metzger AL, et al.: Follow-up study of juvenile chronic polyarthritis with particular reference to histocompatibility antigen W 27. Ann Rheum Dis 1974, 33:289–292.

    Article  PubMed  CAS  Google Scholar 

  23. Cabral DA, Oen KG, Petty RE: SEA syndrome revisited: a longterm follow-up of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992, 19:1282–1285. Thirty-six of 39 children from two centers in Canada initially described as having SEA syndrome were re-evaluated at 11-year follow-up. Among 13 patients who were originally reported has having definite spondylarthropathies, eight had AS, two had IBD, and three had initial reactive arthritis, of whom two were in remission and one had episodic arthritis. Among 23 with SEA syndrome, six had definite AS and six possible AS. The other patients had PsA, juvenile arthritis, SEA syndrome with sustained remission, or various other musculoskeletal conditions.

    PubMed  CAS  Google Scholar 

  24. Burgos-Vargas R, Clark P: Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989, 16:192–197.

    PubMed  CAS  Google Scholar 

  25. Burgos-Vargas R, Vazquez-Mellado J: The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995, 38:835–843. A retrospective review of the records from 35 patients with juvenile onset AS (New York criteria) and from 75 patients with juvenile arthritis excluding type II pauciarticular JA was done. Definite involvement of the spine and sacroiliitis in juvenile-onset AS occurred after a mean follow-up of 7.3 years. Tarsal disease was an important feature at AS onset, before the occurrence of axial involvement.

    Article  PubMed  CAS  Google Scholar 

  26. Kanski JJ: Uveitis in juvenile chronic arthritis. Clin Exp Rheumatol 1990, 8:499–503.

    PubMed  CAS  Google Scholar 

  27. Akduman L, Kaplan HJ, Tyshsen L: Prevalence of uveitis in an outpatient juvenile arthritis clinic: onset of uveitis more than a decade after onset of arthritis. J Pediatr Ophthalmol Strabismus 1997, 34:101–106.

    PubMed  CAS  Google Scholar 

  28. Haas JP, Truckenbrodt H, Paul C, et al.: Subtypes of HLA-DRB1*03, *08, *11,*13 and 14* in early onset pauciarticular juvenile chronic arthritis (EOPA) with and without iridocyclitis. Clin Exp Rheumatol 1994, 12:S7-S14.

    PubMed  Google Scholar 

  29. Melin-Aldana H, Gianninni EH, Taylor J, et al.: Human leukocyte antigen DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr 1992, 121:56–60.

    Article  PubMed  CAS  Google Scholar 

  30. Cabral DA, Petty RE, Malleson PN, et al.: Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 1994, 21:2370–2375. Eighty-two eyes in 49 patients with chronic arthritis were studied after a mean follow-up of 9.4 years. More than 95% of the patients developed uveitis within 5 years of onset of arthritis. In 33% of the patients with ocular complications, normal vision was maintained or correctable in more than 50% of them.

    PubMed  CAS  Google Scholar 

  31. Weiss AH, Wallace CA, Sherry DD: Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133:266–268.

    Article  PubMed  CAS  Google Scholar 

  32. Kilmartin DJ, Forrester JV, Dick AD: Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998, 82:737–742.

    Article  PubMed  CAS  Google Scholar 

  33. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS: Visual outcomes prognosticators in juvenile rheumatoid arthritis associated uveitis. Ophthalmology 1997, 104:236–244.

    PubMed  CAS  Google Scholar 

  34. Valimaki J, Airaksinen PJ, Tuulonen A: Molteno implantation for secondary glaucoma in juvenile rheumatoid arthritis. Arch Ophthalmol 1997, 115:1253–1256.

    PubMed  CAS  Google Scholar 

  35. BenEzra D, Cohen E: Cataract surgery in children with chronic uveitis. Ophthalmology 2000, 107:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  36. Lundvall A, Zetterstrom C: Cataract extraction and intraocular lens implantation in children with uveitis. Br J Ophthalmol 2000, 84:791–793.

    Article  PubMed  CAS  Google Scholar 

  37. Savolainen HA, Lehmati M, Kautiainen H, et al.: HLA-B27: a prognostic factor in juvenile chronic arthritis. Clin Rheumatol 1998, 17:121–124.

    Article  PubMed  CAS  Google Scholar 

  38. David J, Vouyiouka O, Ansell BM, et al.: Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993, 11:85–90. This is the largest published series of patients with amyloidosis secondary to JIA. Treatment with chlorambucil appears to confer long-term survival and remission rates. Long-term side effects on fertility and the increased risk of malignancy deserve the consideration of other effective methods of suppressing the inflammatory process of JIA.

    PubMed  CAS  Google Scholar 

  39. Duston MA, Skinner M, Shirahama T, Cohen AS: Diagnosis of amyloidosis by fat aspiration: analysis of four years’ experience. Am J Med 1986, 82:412–414.

    Article  Google Scholar 

  40. Hawkins PN, Richarson S, Vigushin DM, et al.: Serum amyloid P component scintigraphy and turn over studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993, 36:842–845.

    Article  PubMed  CAS  Google Scholar 

  41. Laiho K, Tiitinen S, Kaarela K, et al.: Secondary amyloidosis has decreased in patients with joint disease in Finland. Clin Rheumatol 1999, 18:122–123.

    Article  PubMed  CAS  Google Scholar 

  42. Bardare M, Falcini F, Hertzberger-Cate R, et al.: Idiopathic limb edema in children with chronic arthritis: a multicenter report of 12 cases. J Rheumatol 1997, 24:384–388.

    PubMed  CAS  Google Scholar 

  43. Schmitt P, Prieur AM, Brunelle F: Juvenile rheumatoid arthritis and lymphedema: lymphangiographic aspects. Pediatr Radiol 1999, 29:364–366.

    Article  Google Scholar 

  44. Davies UM, Rooney M, Preece MA, et al.: Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol 1994, 21:153–158.

    PubMed  CAS  Google Scholar 

  45. Touati G, Prieur AM, Ruiz JC, et al.: Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy, I: Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998, 83:403–409. Fourteen patients were treated with rhGH for 1 year. All patients showed an increase growth velocity from 1.9 to 5.4 cm/year. Lean body mass increased by 12.2% and fat mass excess decreased by 19.5%. After cessation of GH therapy, growth velocity and body composition returned to those before therapy.

    Article  PubMed  CAS  Google Scholar 

  46. Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Mshwal A: Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. J Pediatr Endocrinol Metab 2000, 13:899–905.

    PubMed  CAS  Google Scholar 

  47. Davies UM, Jones J, Reeve J, et al.: Juvenile rheumatoid arthritis: effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 1997, 40:332–340.

    Article  PubMed  CAS  Google Scholar 

  48. Falcini F, Ermini M, Bagnoli F: Bone turnover in children with juvenile rheumatoid arthritis. J Endocrinol Invest 1998, 21:31–36.

    PubMed  CAS  Google Scholar 

  49. Zak M, Hassager C, Lovell DJ, et al.: Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term follow up study. Arthritis Rheum 1999, 42:790–798.

    Article  PubMed  CAS  Google Scholar 

  50. Rooney M, Davies UM, Reeve J, et al.: Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000, 27:1073–1081.

    PubMed  CAS  Google Scholar 

  51. Touati G, Ruiz JC, Porquet D, et al.: Effects on bone metabolism of one year recombinant human growth hormone administration to children with juvenile chronic arthritis undergoing chronic steroid therapy. J Rheumatol 2000, 27:1287–1293.

    PubMed  CAS  Google Scholar 

  52. Glorieux FH, Bishop NJ, Plotkin H, et al.: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339:947–952.

    Article  PubMed  CAS  Google Scholar 

  53. Brumasen C, Hamdy NA, Papapoulos SE: Long-term effects of biphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997, 76:266–283.

    Article  Google Scholar 

  54. Bianchi ML, Cimaz R, Bardare M, et al.: Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000, 43:1960–1966.

    Article  PubMed  CAS  Google Scholar 

  55. Lovel DJ, Gianninni EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342:763–769. Sixty-nine children with polyarticular course of JA were treated with etanercept 0.4 mg/kg twice weekly. Seventy-four percent met response criteria at day 90. In a second part of the study, randomized responders were treated with placebo or were continued on etanercept. Twenty-one of 26 patients receiving placebo had flares after a median time of 28 days, and seven of 25 patients receiving etanercept had flares after a median time of 118 days.

    Article  Google Scholar 

  56. Bloom BJ: Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:2606–2608.

    Article  PubMed  CAS  Google Scholar 

  57. Skytta E, Pohjanskovski H, Savoilainen A: Etanercept and urticaria in patients with juvenile arthritis. Clin Exp Rheumatol 2000, 18:533–534.

    PubMed  CAS  Google Scholar 

  58. Elliott MJ, Woo P, Charles P, et al.: Suppression of fever and acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997, 36:589–596.

    Article  PubMed  CAS  Google Scholar 

  59. Wulffraat NM, Sanders LAM, Kuis W: Autologous hematopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000, 2:316–323. The authors present a comprehensive overview on the results of autologous stem cell transplantation (ASCT) in children with autoimmune diseases. Despite extremely encouraging results in JIA and in few children with SLE and scleroderma, this procedure remains very difficult with a high mortality rate. Proposals are discussed for reducing this very serious problem.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité d’Immunologie, Hématologie et Rhumatologie Pédiatriques, Hôpital Necker Enfants Malades, 149 rue de Sèvres, 75743, Paris cedex 15, France

    Anne-Marie Prieur MD & Gaëlle Chèdeville MD

Authors
  1. Anne-Marie Prieur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaëlle Chèdeville MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prieur, AM., Chèdeville, G. Prognostic factors in juvenile idiopathic arthritis. Curr Rheumatol Rep 3, 371–378 (2001). https://doi.org/10.1007/s11926-996-0006-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-996-0006-6

Keywords

Search

Navigation